23 citations
,
June 2012 in “Molecular Biology Reports” VEGF stimulates hair cell growth and increases growth receptor levels through a specific signaling pathway.
86 citations
,
July 2020 in “International Journal of Molecular Sciences” Activating the Wnt/β-catenin pathway could lead to new hair loss treatments.
222 citations
,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
29 citations
,
January 2021 in “Translational Psychiatry” The research suggests that Tourette syndrome is linked to both brain signaling and immune system pathways.
December 2025 in “ADMET & DMPK” Personalized treatments for hair loss focus on specific genetic and biological pathways.
November 2017 in “Asian journal of pharmaceutical and clinical research” Three compounds from Dadap leaves may help treat hair loss.
119 citations
,
November 2014 in “Trends in Cell Biology” Fibroblast growth factor receptor signaling controls cell development and repair, and its malfunction can cause disorders and cancer, but it also offers potential for targeted therapies.
14 citations
,
July 2021 in “Biomolecules” Centipeda minima extract helps hair grow by activating important growth signals and could be a promising hair loss treatment.
1 citations
,
January 2023 in “Portuguese Journal of Dermatology and Venereology” JAK inhibitors effectively treat skin conditions and topical forms are safer.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
January 2023 in “National Journal of Physiology, Pharmacy and Pharmacology” Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.
January 2021 in “Anais do Congresso Brasileiro de Reumatologia 2020” Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
8 citations
,
June 2022 in “Frontiers in bioengineering and biotechnology” A patch made from human lung fibroblast material helps heal skin wounds effectively, including diabetic ulcers.
4 citations
,
April 2020 in “JAAD case reports” JAK inhibitors help hair regrowth but not fully effective for androgenetic alopecia.
116 citations
,
February 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors help with skin conditions but need more research on dosing and safety.
49 citations
,
August 2018 in “International Journal of Dermatology” Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
37 citations
,
January 2016 in “Drug design, development and therapy” Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.
2 citations
,
December 2023 in “Journal of clinical immunology” Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
37 citations
,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
3 citations
,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
3 citations
,
August 2020 in “Case Reports in Dermatology” Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
2 citations
,
April 2019 in “Dermatologic Therapy” A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
1 citations
,
October 2025 in “Cureus” Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.
January 2026 in “Frontiers in Drug Discovery” Transforming skin disease treatment requires new strategies, better drug models, and patient-focused research.
January 2025 in “Balkan Medical Journal” Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.
March 2024 in “Clinical, cosmetic and investigational dermatology” Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
February 2026 in “Frontiers in Immunology” Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
April 2024 in “Frontiers in physiology” Immune cells are crucial for hair growth and preventing hair loss.
October 2021 in “Research Square (Research Square)” Melatonin affects certain genes and pathways involved in cashmere goat hair growth.